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Abstract Treatment with (neo)adjuvant chemotherapy
for breast cancer, as currently given, causes cell damage by
induction of double-strand DNA breaks. Because BRCA1
and BRCA2 proteins play a role in the repair of DNA
damage, the efficacy of (neo)adjuvant chemotherapy may
be increased in BRCA1/2-associated breast cancer patients.
As a downside, acute chemotherapy-related toxicity may
also be increased. We selected all female patients who
were treated at the Erasmus MC Cancer Institute, with
(neo)adjuvant chemotherapy for primary or locoregional
recurrence of breast cancer (PBC/LR) between January 1,
2004 and December 31, 2014. The primary outcome was
the relative total dose intensity (RTDI), calculated for
anthracyclines and taxanes separately. Secondary outcomes
were the occurrence of febrile neutropenia, delay in
chemotherapy administration, and switch to another
chemotherapy regimen due to toxicity. In total, 701
patients treated for PBC/LR were eligible for data analyses,
among which 85 BRCA1/2 mutation carriers (n = 67
BRCA1 and n = 18 BRCA2). The mean RTDI for anthra-
cyclines was not significantly different between both
groups (98.7 % in the BRCA1/2, 96.6 % in the sporadic
group, p = 0.27). Also the mean RTDI for taxanes was not
significantly different between the groups (93.6 % in the
BRCA1/2-associated, 90.0 % in the sporadic group,
p = 0.12). Linear regression analysis revealed no signifi-
cant effect of BRCA1/2 mutation carriership on the RTDIs.
No significant differences were found in the percentages of
patients presenting with febrile neutropenia, having a delay
in chemotherapy administration or switching to an altered
chemotherapy regimen. Additionally, the odds ratios
showed no significant effect of BRCA1/2 mutation carri-
ership on the secondary outcome variables. (Neo)adjuvant
chemotherapy-related toxicity was not different between
BRCA1/2-associated and sporadic breast cancer patients
suggesting that the DNA damage repair mechanism of non-
cancer cells with only one normal copy of either the
BRCA1 or BRCA2 gene is sufficiently functional to handle
acute chemotherapy-associated toxicity.
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Introduction
Carriers of a germline BRCA1 or BRCA2 (BRCA1/2)
mutation face an increased lifetime risk of developing
breast cancer, estimated to range from 47 to 66 % for
BRCA1 mutation carriers and from 40 to 57 % for BRCA2
mutation carriers [1, 2].
Carriers of a germline BRCA1/2 mutation, by definition,
have one allele with a mutation in the BRCA1/2 gene, while
the gene on the other allele is intact. In normal cells, it
seems that enough BRCA1 or BRCA2 protein is present for
adequate functioning of cells in the various tissues of these
women. However, BRCA1/2-associated breast cancers
often have lost the wild-type allele through somatic alter-
ations during tumor development. As a consequence, there
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is no functional BRCA1 or BRCA2 protein in these tumor
cells. Since BRCA1 and BRCA2 proteins are essential in
the repair of double-strand DNA breaks (DSBs) by
homologous recombination [3, 4], treatments which cause
DSBs might be more effective in BRCA1/2-associated than
in sporadic breast cancer patients, which tumor cells mostly
have an intact homologous recombination repair system.
The platinum derivates carboplatin and cisplatin, both
strong inducers of DSBs, indeed showed higher efficacy in
BRCA1/2-associated compared to sporadic breast cancer
patients [5–7]. Although less pronounced, anthracyclines
are also known to induce indirect DSBs by inhibiting
topoisomerases, causing DNA interstrand cross-links and
the generation of free radicals [8]. Accordingly, several
clinical studies have shown increased sensitivity for
anthracycline-containing chemotherapy in BRCA1/2
mutation carriers [9–11].
An important question is whether acute toxicity due to
(neo)adjuvant chemotherapy is different in BRCA1/2
mutation carriers treated for breast cancer when compared
with sporadic breast cancer patients. Since (neo)adjuvant
chemotherapy induces massive DNA damage also in nor-
mal cells, one might argue that the amount of functional
BRCA1 or BRCA2 protein in mutation carriers is too low
to repair all the DNA damage created, compared to spo-
radic breast cancer patients, resulting in more toxicity.
Thus far two studies investigated the acute toxicity of
(neo)adjuvant chemotherapy in BRCA1/2-associated,
compared to sporadic breast cancer patients, with incon-
sistent results [12, 13]. In the retrospective study of
Shanley et al., comparing 62 BRCA1/2 mutation carriers
with breast cancer to 62 matched sporadic breast cancer
cases, a large proportion of patients (80/124; 65 %) was
treated with older chemotherapy regimens without anthra-
cyclines, while no patient was treated with taxanes. In
BRCA2 mutation carriers, less hematologic toxicity and
dose alterations were observed compared to both BRCA1-
associated and sporadic breast cancer patients, while no
differences were seen for BRCA1-associated versus spo-
radic patients [12]. In the study by Huszno et al., com-
paring 41 BRCA1/2-associated with 229 breast cancer
patients without a BRCA1/2 mutation, all patients were
treated with an anthracycline-based regimen and also
patients treated with taxanes were included [13]. It was
found that the proportion of patients with neutropenia at the
planned start date of the second chemotherapy cycle was
significantly higher in breast cancer patients with a BRCA1/
2 mutation compared to patients without a BRCA1/2
mutation. Twelve patients (4.5 %), all in the group of
patients without a BRCA1/2 mutation, required early ter-
mination of treatment due to chemotherapy toxicity, mostly
because of grade 3-4 neutropenia. Nausea and vomiting
were seen more often in patients without a BRCA1/2
mutation. There were no differences in the other investi-
gated variables (anemia, diarrhea, and mucositis).
Nowadays, standard (neo)adjuvant chemotherapy regi-
mens for breast cancer contain both anthracycline (either
epirubicin or doxorubicin) and taxanes (either paclitaxel or
docetaxel). In view of the sparse available data on toxicity
of taxanes and currently used chemotherapy regimens in
BRCA1/2 mutation carriers, we performed a larger single-
center retrospective cohort study to examine potential
differences in (neo)adjuvant chemotherapy-associated




For this retrospective cohort study, we selected from the
hospital pharmacy prescription registry all female patients
who were treated at the Erasmus MC Cancer Institute,
Rotterdam, The Netherlands, with adjuvant or neoadjuvant
chemotherapy for primary breast cancer or local/locore-
gional recurrence (PBC/LR). Further eligibility criteria
concerned: chemotherapy regimen consisting of anthracy-
clines and/or taxanes and chemotherapy treatment started
between January 1, 2004 and December 31, 2014. Patients
who were previously treated with chemotherapy for either
breast or another invasive cancer were not excluded, but
subgroup analyses were performed with the exclusion of
these patients, since pre-treated patient might have
increased hematologic toxicity. Patients treated with
(neo)adjuvant chemotherapy twice in the time period of the
study were included for both episodes of chemotherapy
treatment. Eleven PBC/LRs were excluded because of
missing data concerning chemotherapy administration,
leaving a total of 704 PBC/LRs (in 701 patients) eligible
for the primary analysis (Fig. 1).
For eligible patients, data on tumor characteristics (type
of histology, differentiation grade, estrogen receptor status,
progesterone receptor status, HER2 status and stage) and
treatment details (surgery, radiotherapy, and/or chemother-
apy) were retrieved. We also collected specific data on
chemotherapy treatment (treatment regimen, dosing, delays,
alterations, and complications). Data on mutation status were
collected from the institutional database of the family cancer
clinic. Patients not tested for a BRCA1/2 mutation were
considered as sporadic breast cancer patients.
Chemotherapy regimens
During the time period of the study, the chemotherapy
regimens were not different for BRCA1/2 mutation carriers
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and sporadic patients. Patients were treated with systemic
therapy based on the national guidelines. For patients with
HER2-negative breast cancer, the standard regimens at
start of the study contained anthracyclines but no taxanes.
From July 2008 till the end of the study, standard regimen
for node-positive patients included taxanes (3-weekly
docetaxel), while for node-negative patients, taxanes (3-
weekly docetaxel) were included in the standard regimen
from October 2011 onwards. Patients with HER2-positive
breast cancer were treated with anthracyclines and no
taxanes till August 2006. Trastuzumab was added to this
regimen from September 2005 onwards. From August 2006
till the end of the study, the standard regimen contained
anthracyclines and taxanes (weekly paclitaxel) in combi-
nation with trastuzumab.
Some patients were treated with other schemes because
of participation in a clinical trial, prior chemotherapy
treatment, or comorbidities. Standard G-CSF (granulocyte
colony-stimulating factor) prophylaxis was only used for
six cycles of TAC (docetaxel, doxorubicin, and
cyclophosphamide) and dose-dense regimens (AC, dox-
orubicin/cyclophosphamide, given every 2 weeks). In case
of febrile neutropenia or persisting neutropenia at planned
start of next chemotherapy cycle, G-CSF was added to the
next treatment cycle. In case of febrile neutropenia or
persisting neutropenia at planned start of next chemother-
apy cycle in patients treated with G-CSF, dose reduction
was considered. Furthermore, dose reduction and/or dose
delay were considered based on the severity of hemato-
logical and non-hematological toxicities.
Toxicity outcomes
Primary outcome was the relative total dose intensity
(RTDI), a measure of delivered (actual) total dose intensity
(ATDI; i.e. administered dose over the total time course of
treatment), relative to the planned total dose intensity
(PTDI). The RTDI, therefore, expresses the effect of
reductions, delays, as well as premature discontinuations of
a treatment. The RTDI was calculated separately for
anthracyclines and taxanes.
RTDI was calculated based on an adaptation of the
formula described by Loibl et al. [14], and defined as the
ratio of the ATDI and the PTDI, expressed as a percentage:
RTDI ð%Þ ¼ ATDI
PTDI
 100%
The ATDI was defined as the actual total dose intensity
over the real treatment duration, expressed as percent-
age/day. In case of permanent treatment discontinuation,
   Primary analysis 
Selecon criteria: Primary breast cancer and/or local/locoregional recurrence, 
in female paents treated with (neo)adjuvant chemotherapy (anthracyclines 
and/or taxanes) between 1-1-2004 and 31-12-2014 







• Missing data regarding chemotherapy 
doses and/or administraon, n=9 
• Missing data regarding chemotherapy doses 
and/or administraon, n=2 
Sporadic 
N=618 
(in 616 paents) 
BRCA2 
N=18 
(in 18 paents) 
BRCA1 
N=68 
(n 67 paents) 
Fig. 1 Study population
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the remaining cycles were calculated with the planned
length and zero dose:
ATDI % dayð Þ ¼ Sum of % of delivered dose per cycle
Duration of therapy daysð Þ
The PTDI was defined as the planned total dose intensity
over the entire treatment duration, expressed as %/day:
PTDI ð%=dayÞ ¼
100%  Number of planned treatment cycles
Planned duration of therapy ðdaysÞ
The secondary outcomes were the occurrence of one or
more episodes of febrile neutropenia, of one or more delays
in chemotherapy administration (either due to anthracy-
cline-related toxicity or taxane-related toxicity) and of
switch to another chemotherapy regimen.
Statistical analyses
We evaluated characteristics of patients, tumors and
chemotherapy regimens, as well as outcome variables by
comparing patients with proven BRCA1/2-associated breast
cancer (BRCA1/2 group) with those with sporadic breast
cancer (sporadic group). For categorical variables, Pear-
son’s Chi square test was used to test for significant dif-
ferences between the two groups, and the two-sample
Wilcoxon rank-sum (Mann–Whitney) test was used for
differences between continuous variables.
To quantify the effect of carrying a BRCA1/2 gene
mutation on the RTDI of anthracyclines and taxanes, we
performed univariate linear regression analyses. To esti-
mate the effect of mutation carriership on the other end-
points (i.e. a delay in administration of chemotherapy,
febrile neutropenia, and an alteration of the chemotherapy
scheme due to toxicity), we used logistic regression
models to obtain odds ratios (ORs) and accompanying
95 % confidence intervals (CIs), using treatments for
PBC/LRs in sporadic patients as the reference group. To
adjust for other variables, we fitted multivariate regres-
sion models. We considered age at start of chemotherapy,
previous chemotherapy, radiotherapy before chemother-
apy, neoadjuvant chemotherapy, and number of admin-
istered chemotherapy cycles as potential confounders. We
incorporated a variable in a regression model if (1) there
was a significant difference in the median or in the dis-
tribution of the respective variable between the BRCA1/2-
associated and the sporadic group and (2)—for linear
regression models—univariate analysis of the respective
variable showed a significant association with the out-
come, or—for logistic regression models—the likelihood
ratio test showed that the model including the respective
variable was significantly different from the model with-
out the variable.
All p values were two-sided, and a significance level
a = 0.05 was used. Analyses were performed with
STATA (version 13.1; StataCorp, College Station, TX,
USA).
Results
In total, 701 patients were eligible for data analyses, of
whom one BRCA1 mutation carrier and two sporadic
patients were treated with two separate episodes of
(neo)adjuvant chemotherapy for a PBC/LR during the
study period. Tables 1 and 2 depict the patient and tumor
characteristics, and the treatment features, respectively. 85
patients (12 %) were BRCA1/2 mutation carriers (n = 67
BRCA1 and n = 18 BRCA2). The median age at start of
chemotherapy was significantly lower in the BRCA1/2
group compared to the sporadic group (38 years [range
21–64] vs. 51 years [range 23–77], respectively,
p\ 0.001). PBC/LRs in BRCA1/2 mutation carriers more
often showed high differentiation grade (Bloom/Richard-
son grade 3), triple-negative tumors and negative lymph
node status compared to PBC/LRs in sporadic patients. For
a total of 492 PBC/LRs (70 %), treatment with both
anthracycline- and taxane-containing chemotherapy was
applied, while chemotherapy consisted of anthracyclines
with no taxanes for 193 PBC/LRs (27 %) and for 19 PBC/
LRs (3 %) of taxanes with no anthracyclines. In the
BRCA1/2 group, more patients were previously treated
with chemotherapy for breast cancer or for another inva-
sive malignancy (13 vs. 5 % in the sporadic group,
p = 0.004; Table 2).
Primary outcome
The mean RTDI for anthracyclines was high, without sig-
nificant differences between the BRCA1/2 and the sporadic
groups (98.7 and 96.6 %, respectively, p = 0.27; Table 3).
The mean RTDI for taxanes was slightly lower than for
anthracyclines, but again without significant differences
between the two groups (93.6 % in the BRCA1/2 group and
90.0 % in the sporadic group, p = 0.12; Table 3). As
illustrated in Fig. 2, BRCA1/2 mutation carriers showed
less variability in the RTDI than sporadic patients. As
shown in Table 4, the linear regression models revealed no
significant effect of BRCA1/2 mutation carriership on the
RTDIs.
Secondary outcomes
As shown in Table 3, no significant differences between
the BRCA1/2-associated and sporadic groups were found
in the percentage of patients presenting with febrile
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Table 1 Patient and tumor characteristics
BRCA1/2 mutation




Year of birth, median (range) 1971 (1942–1990) 1957 (1936–1987) \0.001
Year of birth, n (%)
1930–1939 0 (0) 8 (1) \0.001
1940–1949 4 (5) 130 (21)
1950–1959 15 (18) 205 (33)
1960–1969 18 (21) 188 (31)
1970–1979 30 (35) 66 (11)
1980–1989 17 (20) 19 (3)
1990–1999 1 (1) 0 (0)
Ethnicity, n (%)
East Asian 0 (0) 17 (3) 0.33
Black 6 (7) 36 (6)
White 79 (93) 557 (90)
Other 0 (0) 6 (1)
BRCA mutation, n (%)
BRCA1 67 (79) – –
BRCA2 18 (21) – –
PBC/LRs in BRCA1/2
mutation carriers (n = 86)
PBC/LRs in sporadic
patients (n = 618)
Age at start chemotherapy, median (range) 38 (21–64) 51 (23–77) \0.001
Age at start chemotherapy, n (%)
20–29 years 12 (14) 15 (2) \0.001
30–39 years 34 (40) 61 (10)
40–49 years 23 (27) 179 (29)
50–59 years 12 (14) 221 (36)
60–69 years 5 (6) 136 (22)
70–79 years 0 (0) 6 (1)
Body surface area (m2), median (range) 1.8 (1.4–2.3) 1.8 (1.4–2.6) 0.41
Histologic subtype, n (%)
Ductal 74 (88) 521 (86) 0.005
Lobular 1 (1) 58 (10)
Other 9 (11) 30 (5)
Unknown 2 9
Histologic grade (Bloom/Richardson), n (%)
1 4 (5) 48 (8) \0.001
2 13 (16) 265 (46)
3 64 (79) 269 (46)
Unknown 5 36
Receptor status, n (%)
Triple-negative 51 (60) 101 (17) \0.001
Estrogen receptor positive 32 (37) 466 (75) \0.001
HER2-positive 4 (5) 135 (22) \0.001
Lymph node status, n (%)
N0 55 (65) 228 (38) \0.001
N1 21 (25) 254 (43)
N2 4 (5) 78 (13)
N3 4(5) 37 (6)
Unknown 2 21
PBC/LR Primary breast cancer or local/locoregional recurrence
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neutropenia (21 and 17 %, respectively, p = 0.42),
having a delay in chemotherapy administration due to
chemotherapy toxicity (for anthracyclines: 15 % in both
groups, p = 0.97; for taxanes: 4 % in the BRCA1/2-
associated, and 10 % in the sporadic group, p = 0.13) or
switching to an altered chemotherapy regimen due to
chemotherapy toxicity (9 % in the BRCA1/2-associated
and 11 % in the sporadic group, p = 0.73). Additionally,
Table 2 Features of (neo)adjuvant chemotherapy and other treatments
PBC/LRs in BRCA1/2 mutation carriers
(n = 86)
PBC/LRs in sporadic patients
(n = 618)
p value
Planned chemotherapy regimen, n (%)
Containing both anthracyclines and taxanes 49 (57) 443 (72) \0.001
3 9 FE100C/3 9 D 46 (53) 290 (47)
4 9 AC/12 9 P 1 (1) 103 (17)
6 9 TAC 1 (1) 40 (6)
Other 1 (1) 10 (2)
Containing anthracyclines and no taxanes 30 (35) 163 (26)
5 9 FE90C 19 (22) 86 (14)
6 9 FE90C 7 (8) 60 (10)
4 9 AC 1 (1) 13 (2)
Other 3 (3) 4 (1)
Containing taxanes and no anthracyclines 7 (8) 12 (2)
Dose-dense regimens, n (%) 3 (3) 1 (0.2) \0.001
Regimens with standard G-CSF prophylaxis,
n (%)
4 (5) 41 (7) 0.48
Regimens with weekly chemotherapy, n (%) 1 (1) 104 (17) \0.001
Number of 3-weekly chemotherapy cycles,
median (range)
6 (3–10) 6 (1–8) 0.14
Previous chemotherapy, n (%) 11 (13) 31 (5) \0.01
Adjuvant radiotherapy before chemotherapy,
n (%)
2 (2) 87 (14) \0.01
Neoadjuvant chemotherapy, n (%) 10 (12) 81 (13) 0.70
PBC/LR primary breast cancer or local/locoregional recurrence, 3 9 FE100C/3 9 D three cycles of 3-weekly fluorouracil 500 mg/m2, epirubicin
100 mg/m2 and cyclophosphamide 500 mg/m2, followed by three cycles of docetaxel 100 mg/m2, 4 9 AC/12 9 P four cycles of 3-weekly
doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, followed by 12 cycles of weekly paclitaxel 80 mg/m2, 6 9 TAC six cycles of 3
weekly docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2, 5 9 FE90C five cycles of 3-weekly fluorouracil
500 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 500 mg/m2, 6 9 FE90C six cycles of 3-weekly fluorouracil 500 mg/m2, epirubicin
90 mg/m2 and cyclophosphamide 500 mg/m2, 4 9 AC four cycles of 3-weekly doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, G-
CSF granulocyte colony-stimulating factor
Table 3 Primary and secondary outcome variables
PBC/LRs in BRCA1/2 mutation
carriers (n = 86)
PBC/LRs in sporadic patients
(n = 618)
p value
Mean relative total dose intensity, % (SD)
Anthracyclines 98.7 (3.7) 96.6 (10.5) 0.27
Taxanes 93.6 (17.6) 90.0 (19.9) 0.12
Febrile neutropenia, n (%) 18 (21) 107 (17) 0.42
Delay of chemotherapy administration, n (%)
Because of anthracyclines 12 (15) 90 (15) 0.97
Because of taxanes 2 (4) 46 (10) 0.13
Alteration of chemotherapy scheme, n (%) 8 (9) 65 (11) 0.73
PBC/LR Primary breast cancer or local/locoregional recurrence, SD standard deviation
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the ORs yielded by logistic regression showed no sig-
nificant effect of BRCA1/2 mutation carriership on the
secondary outcome variables (Table 5).
Subgroup analyses
To exclude effect modification by differences in treatment
regimens between the two groups on the outcome variables,
we performed analyses with exclusion of certain
chemotherapy regimens. Exclusion of the patients being
treated with regimens administered with standard G-CSF
prophylaxis (n = 4 treated with dose-dense regimens;
n = 41 treated with TAC), with regimens consisting of
weekly chemotherapy administration (n = 105) or with
regimens containing taxanes with no anthracyclines
(n = 19) did not significantly influence the results of both
primary and secondary outcome variables (data not shown).
Febrile neutropenia was then found in 25 % of the BRCA1/
2-associated and in 20 % of the sporadic group, p = 0.57.
Excluding the patients who were previously treated with
adjuvant chemotherapy for breast cancer or for another
invasive cancer (n = 42) also did not significantly influ-
ence the results of both primary and secondary outcome
variables (data not shown). When taking the BRCA1/2-
associated and the sporadic group together, the RTDI was
not significantly different between patients previously
versus not previously treated with chemotherapy (for
anthracyclines RTDI: 96.8 % in both groups, p = 0.80; for
taxanes RTDI: 95.8 vs. 90.1 %, p = 0.20).
Discussion
In this single-center retrospective cohort study, we found no
differences in RTDI of (neo)adjuvant chemotherapy (both
for anthracyclines and taxanes) between BRCA1/2-associ-
ated and sporadic breast cancer patients. Furthermore, we
found no differences in the occurrence of febrile neutrope-
nia, in delay of chemotherapy administration or in alteration
Fig. 2 Relative total dose intensity (%) for a anthracyclines and
b taxanes, separately for BRCA1/2-associated and sporadic breast
cancer patients
Table 4 Linear regression
analyses for mean relative total
dose intensity
Univariate model Multivariate model
Coefficient (SE) p value Coefficient (SE) p value
Mean RTDI anthracyclines (%)
BRCA1/2 versus sporadic 1.69 (1.08) 0.12 Not applicablec
Age at start chemotherapy -0.05 (0.03) 0.12
Previous chemotherapya -1.09 (1.84) 0.55
Radiotherapy before chemotherapyb -1.16 (1.00) 0.25
Mean RTDI taxanes (%)
BRCA1/2 versus sporadic 3.94 (2.98) 0.19 3.33 (2.97) 0.26
Age at start chemotherapy -0.10 (0.08) 0.22 – –
Previous chemotherapya 6.71 (4.17) 0.11 – –
Radiotherapy before chemotherapyb -6.77 (2.75) 0.01 -6.50 (2.76) 0.02
RTDI Relative total dose intensity, SE standard error
a Versus no previous chemotherapy
b Versus no radiotherapy before chemotherapy
c None of the variables were associated with the outcome variable
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of the chemotherapy regimen due to toxicity between the
two groups. Our observations on the absence of increased
acute toxicity due to (neo)adjuvant chemotherapy in
BRCA1/2 mutation carriers, compared to sporadic breast
cancer patients, suggest that the DNA damage repair
mechanism of non-cancer cells with only one normal copy
of either the BRCA1 or BRCA2 gene is sufficiently func-
tional to handle acute chemotherapy-associated toxicity.
Our results have to be interpreted in the light of the two
previously published studies on chemotherapy-associated
toxicity in BRCA1/2 mutation carriers. Huszno et al. found
more neutropenia at the planned date of the second
chemotherapy cycle in BRCA1/2-associated (n = 41) than
in sporadic breast cancer patients (n = 229) [13]. It is
unclear what the clinical relevance of this finding is, since
they did not mention the proportion of patients needing
dose reductions, experiencing delay in chemotherapy
administration and febrile neutropenia. We choose to use
more clinically relevant outcome measures such as dose
intensity which is likely to be associated with efficacy [15]
and febrile neutropenia that might have consequences for
the subsequent cycle. The data of the study of Shanley
et al., not finding increased chemotherapy-associated tox-
icity in BRCA1/2-associated (n = 62) compared to spo-
radic breast cancer patients (n = 62) [12], are hardly
comparable to our study observations, since a large part of
their patients were treated with older chemotherapy
regimens.
To the best of our knowledge, our study is the largest
published on this topic so far. We did not find any differ-
ences in clinically relevant toxicity measures after treat-
ment with anthracyclines and/or taxanes between BRCA1/
2-associated and sporadic breast cancer patients. In both
previous studies, as well as in our study, age at the start of
chemotherapy was significantly lower in the BRCA1/2
group than in the sporadic group. Although increased risk
of myelosuppression at increased age of administration has
been previously reported [16], in our study no difference
was seen in mean RTDI comparing BRCA1/2 mutation
carriers aged [50 years to BRCA1/2 mutation carriers
younger than 50 years (data not shown).
In the BRCA1/2 group more patients were previously
treated with adjuvant chemotherapy than in the sporadic
group, mainly for an earlier primary breast cancer. Since
there is a maximum cumulative dose for anthracyclines, a
relevant proportion of these patients did receive a non-
anthracycline-containing regimen. One might expect
increased toxicity when patients are treated for a second
time with chemotherapy. Leaving out all pre-treated
patients, however, did not influence the results, and com-
paring previously treated patients with non-previously
treated patients (irrespective of BRCA1/2 mutation status)
showed no significant differences in the RTDI, suggesting
that previous treatment with chemotherapy does not
increase acute chemotherapy-related toxicity.
In the BRCA1/2-associated group, fewer patients were
treated with weekly chemotherapy regimens and with
regimens containing standard G-CSF prophylaxis. How-
ever, exclusion of patients treated with these regimens did
not significantly influence the results. The percentage of
patients presenting with febrile neutropenia in the sporadic
group increased in the subgroup analyses, compared to the
percentage found in the primary analysis, which might be
explained by the fact that in the sporadic group a larger
proportion of patients were treated with regimens con-
taining standard G-CSF prophylaxis.
We are aware of a number of shortcomings to be men-
tioned. Despite the fact that our study is the largest pub-
lished on this topic with inclusion of 86 PBC/LRs in
BRCA1/2-associated patients, being 12 % of the total study
group, this number is still quite low. The numbers were too
small to perform useful analyses for BRCA1 and BRCA2
mutation carriers separately, which would be of interest
since BRCA1 and BRCA2 proteins have different roles in
the DNA repair mechanism and the cell cycle. Neverthe-
less, it is unlikely that a clinically relevant difference will
Table 5 Logistic regression
analyses for secondary outcome
variables
Univariate model
odds ratio (95 % CI)
Multivariate model
odds ratio (95 % CI)
Febrile neutropenia 1.27 (0.71–2.27) 1.11 (0.59–2.07)a
Delay of chemotherapy administration
Because of anthracyclines 0.99 (0.50–1.97) Not applicableb
Because of taxanes 0.36 (0.08–1.54) Not applicableb
Alteration of chemotherapy scheme 0.80 (0.33–1.93) Not applicableb
Sporadic breast cancer patients as references versus breast cancer patients with a BRCA1/2 mutation
CI confidence interval
a Adjusted for age at start chemotherapy. The other variables did not meet the criteria for incorporation in
the multivariate model
b No variables did meet the criteria for incorporation in the multivariate model as described in the methods
section
564 Breast Cancer Res Treat (2016) 156:557–566
123
be found with higher numbers of patients, since the RTDI,
especially for anthracycline is very high. In contrast to the
study of Huszno et al., not all our patients were tested for a
BRCA1/2 mutation, but we expect, if any, only a small
proportion of BRCA1/2 mutation carriers in the sporadic
subgroup, since at our institution (and in The Netherlands)
patients are already tested with a low suspicion of BRCA1/
2 mutation carriership. Further, in the current study, we did
not include non-hematologic toxicity as an outcome, since
it is well known that these outcome variables are more
prone to inter-observer variability and are less clinically
relevant when they do not lead to dose delay or dose
reduction [17]. For the same reason, we did not include
hematologic laboratory values measured at planned start of
a new cycle, since these are only relevant when they lead to
dose reduction, delay in chemotherapy administration, or
alteration of chemotherapy regimen. It could have been of
scientific interest to compare neutrophil nadir levels
between BRCA1/2 mutation carriers and sporadic patients.
Unfortunately, due to the retrospective nature of our data,
these data are lacking.
Recent data showed increased efficacy of platinum deri-
vates in patients with triple-negative breast cancer and/or a
BRCA1/2 mutation, leading to incorporation of carboplatin
in standard (neo)adjuvant chemotherapy regimens in this
population [5–7]. These studies did not report on differences
in toxicity between BRCA1/2 mutation carriers and sporadic
breast cancer patients. In our study, the number of patients
treated with carboplatin was very low and no conclusions
can be drawn hereon. Poly ADP-ribose polymerase (PARP)
inhibitors are an important new class of targeted anti-cancer
drugs which induce DSBs in tumors with homologous
recombination deficiency due to, for example, a mutation in
one of the BRCA genes. Recently, the first PARP inhibitor
has been approved for the treatment of BRCA1/2-associated
ovarian cancer, while trials in early and metastatic breast
cancer are ongoing. Lederman et al. compared toxicity of
the PARP inhibitor olaparib in BRCA1/2 mutation carriers
and sporadic patients with ovarian cancer and found no
differences in toxicity [18]. Both platinum derivates and
PARP inhibitors have a much higher capacity to induce
DSBs, compared to anthracyclines. Therefore, further
research on the toxicity of these regimens in BRCA1/2
mutation carriers compared to sporadic patients is war-
ranted, especially since these drugs will be increasingly used
in the treatment of BRCA1/2-associated breast cancer.
Conclusion
In conclusion, there seems no clinically relevant difference in
toxicity of anthracycline- and taxane- containing (neo)adju-
vant chemotherapy regimens for BRCA1/2-associated
compared to sporadic breast cancer patients, which suggests
that the DNA damage repair mechanism of non-cancer cells
with only one normal copy of either the BRCA1 or BRCA2
gene is sufficiently functional to handle acute chemotherapy-
associated toxicity.
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